Wedbush Reiterates Outperform on Elevation Oncology, Maintains $8 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll reiterated an Outperform rating on Elevation Oncology (NASDAQ:ELEV) and maintained an $8 price target.

May 03, 2024 | 1:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll reiterated an Outperform rating on Elevation Oncology and maintained an $8 price target.
The reiteration of an Outperform rating and maintenance of an $8 price target by a reputable analyst like Robert Driscoll from Wedbush is likely to instill confidence among investors about Elevation Oncology's prospects, potentially leading to a positive short-term impact on the stock's price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100